Special Issue "Rheumatoid Arthritis Prevention and Control"
A special issue of Healthcare (ISSN 2227-9032).
Deadline for manuscript submissions: 30 April 2021.
Interests: Preclinical and early rheumatoid arthritis (RA); RA prevention; Ultrasound and MRI; Palindromic rheumatism; Mucosal autoimmunity and RA; Clinical trials in RA
Interests: Inflammatory Arthritis including RA; psoriatic arthritis; AS; SLE; Scleroderma; Sjogren Syndrome; immunotherapy; disease prevention; ultrasound; MRI
The management of rheumatoid arthritis (RA) has been revolutionised by the early arthritis paradigm, with prompt identification and treatment now the central focus of RA clinical care around the world. Despite this approach and despite the array of treatments available, only a minority of patients achieve sustained disease remission. An even smaller proportion realise the ultimate goal of drug-free remission.
In addition to the long held ambition of controlling clinically established arthritis, the recognition of a preclinical phase of RA has now raised the exciting prospect of arthritis prevention. Biomarkers such as autoantibodies, clinical symptoms and high-resolution imaging can be used to accurately identify individuals who are "at-risk" of developing RA. Studying cohorts of at-risk individuals also provides unique insights into the pathobiology of RA, which will inform preventative strategies.
Prevention and cure are arguably the major unmet needs in RA. For the prevention of RA, there are many important questions to address. How do specific risk factors influence the pathobiology of RA, and which should we target to prevent arthritis? What drives RA-related autoimmunity, and how significant is the development of subclinical joint inflammation on imaging? Do at-risk individuals want to undertake preventative interventions? In those individuals in whom arthritis cannot be prevented, optimal control and drug free remission becomes the ambition. How can this be achieved using the therapies currently available to us?
In this Special Issue, we aim to address these intriguing areas, which are major contemporary challenges in rheumatology research and practice.
Dr. Kulveer Mankia
Prof. Dr. Paul Emery
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Rheumatoid arthritis
- Preclinical disease